BeyondSpring Inc.

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On June 4, 2026, BeyondSpring Inc. (the “Company”) announced certain leadership transitions: (b) Transition from Chief Executive Officer. Dr. Lan Huang, the current Chief Executive Officer and Chair of the Board of Directors (the “Board”) of the Company, will transition from her role as Chief Executive Officer, effective July 1, 2026. Dr. Huang will continue to serve the Company in a focused capacity as the Chair of the Board. In connection with this transition, all of Dr. Huang’s unvested equity and long-term incentive awards will be forfeited effective July 1, 2026. (c) Appointment of Chief Executive Officer and Chief Financial Officer. Mr. Min Qiu, age 43, is appointed Chief Executive Officer of the Company, effective July 1, 2026. Mr. Qiu has been actively involved in the Company’s corporate development for the past five years in the position of Vice General Manager of Dalian Wanchunbulin Pharmaceutical Co., Ltd. (“Wanchunbulin”), a subsidiary of the Company, a role he has held since April 2026 and previously from August 2020 to August 2023. From September 2023 to March 2026, Mr. Qiu worked as an independent advisor specializing in capital markets and investment advisory. He previously served as Board Secretary of Guangyuyuan Chinese Herbal Medicine Co., Ltd. (SH: 600771) and as a healthcare analyst at China Merchants Securities, focused on the China-Japan pharmaceutical sector. He holds a Bachelor of Pharmacy and a Master of Engineering in Technology Management for Innovation from the University of Tokyo. Ms. Na Li, age 49, is appointed Chief Financial Officer of the Company, effective July 1, 2026. Ms. Li has served as Chief Financial Officer of Wanchunbulin since November 2020. She holds an Accountant Certificate, a CFO Qualification Certificate, and a Shanghai Stock Exchange Board Secretary Qualification Certificate. She previously served as Board Secretary of a Main Board-listed Chinese pharmaceutical company on the Shanghai Stock Exchange and a Third Board-listed company on the Beijing Stock Exchange. There are no family relationships between Mr. Qiu or Ms. Li and any director or executive officer of the Company that would be required to be disclosed pursuant to Item 401(d) of Regulation S-K or any other arrangements or understandings between Mr. Qiu or Ms. Li and any other person that would be required to be disclosed pursuant to Item 401(b) of Regulation S-K, and there are no transactions between Mr. Qiu or Ms. Li and the Company that would be required to be disclosed pursuant to Item 404(a) of Regulation S-K. As of the date of this report, the Company has not finalized the employment agreements or compensatory arrangements for Mr. Qiu in connection with his appointment as Chief Executive Officer, or for Ms. Li in connection with her appointment as Chief Financial Officer. The Company will file an amendment to this Current Report on Form 8-K to disclose such compensatory arrangements within four business days after they are determined and finalized. (d) Appointment of Vice Chair of the Board. Dr. Jiangwen Majeti, the current Chair of the Nominating and Corporate Governance Committee of the Board and a member of the Compensation Committee of the Board, is appointed Vice Chair of the Board, effective July 1, 2026. In connection with this appointment, the Board approved a one-time grant to Dr. Majeti of share options to purchase 100,000 shares of the Company’s ordinary shares which will vest in four equal annual installments following the grant date. The share options will be granted pursuant to the terms and conditions of the Company’s 2017 Omnibus Incentive Plan and the standard form of option agreement.

Item 7.01. Regulation FD Disclosure. On June 4, 2026, the Company issued a press release relating to the matters described above in Item 5.02. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Item 7.01 of Form 8-K, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any of the Company’s filings under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.